Is new drug prescribing in primary care specialist induced?

BMC Health Services Research

Volumn 9, Issue , 2009, Pages

  Florentinus, Stefan R ^a   Heerdink, Eibert R ^a   Van Dijk, Liset ^b   Griens, Amg Fabiënne ^d   Groenewegen, Peter P ^b,c   Leufkens, Hubert Gm ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Foundation for Pharmaceutical Statistics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CLINICAL PRACTICE; DRUG UTILIZATION; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MASS COMMUNICATION; MEDICINE; MIDDLE AGED; NETHERLANDS; PRESCRIPTION; PRIMARY HEALTH CARE; PUBLIC HEALTH; PUBLIC RELATIONS; STATISTICS;

AGED; DIFFUSION OF INNOVATION; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; SPECIALTIES, MEDICAL;

EID: 61849136114     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-9-6     Document Type: Article

References (27)

1. Prescriber profile and post-marketing surveillance. W Inman G Pearce, Lancet 1993 342 658 661 10.1016/0140-6736(93)91763-C 8103150
2. Physician and practice characteristics associated with the early utilization of new prescription drugs. R Tamblyn P McLeod JA Hanley N Girard J Hurley, Med Care 2003 41 895 908 10.1097/00005650-200308000-00004 12886170
3. Prescriber profile and postmarketing surveillance. HG Leufkens J Urquhart, Lancet 1993 342 1178 10.1016/0140-6736(93)92163-N 7901502
4. Buccaling under the pressure: influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care. AJ Pryce HF Heatlie SR Chapman, BMJ 1996 313 1621 1624 8991012
5. A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing costs. AJ Avery S Rodgers T Heron R Crombie D Whynes M Pringle D Baines R Petchey, BMJ 2000 321 276 81 10915132 10.1136/bmj.321.7256.276
6. Changes in drug treatment after discharge from hospital in geriatric patients. RA Cochrane AR Mandal M Ledger-Scott R Walker, BMJ 1992 305 694 6 1393119
7. Auditing GPs' prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. CS de Vries NM van Diepen TF Tromp LT de Jong-van den Berg, Eur J Clin Pharmacol 1996 50 349 52 10.1007/s002280050121 8839654
8. The influence of hospital-based prescribers on prescribing in general practice. J Feely R Chan J McManus B O'Shea, Pharmacoeconomics 1999 16 175 81 10.2165/00019053-199916020-00006 10539398
9. The impact of specialists on prescribing by general practitioners. J Robertson JL Fryer DL O'Connell A Sprogis DA Henry, Med J Aust 2001 175 407 11 11700832
10. The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem? MA Friedman J Woodcock MM Lumpkin JE Shuren AE Hass LJ Thompson, JAMA 1999 281 1728 1734 10.1001/jama.281.18.1728 10328074
11. The Safety of New Medicines: The Importance of Asking the Right Questions. AJJ Wood, JAMA 1999 281 1753 1754 10.1001/jama.281.18.1753 10328077
12. Monitoring health inequalities through general practice: the Second Dutch National Survey of General Practice. GP Westert FG Schellevis DH de Bakker PP Groenewegen JM Bensing J van der Zee, Eur J Public Health 2005 15 59 65 10.1093/eurpub/cki116 15788805
13. Shared help seeking behaviour within families: a retrospective cohort study. M Cardol PP Groenewegen DH de Bakker P Spreeuwenberg L van Dijk W van den Bosch, BMJ 2005 330 882 15772114 10.1136/bmj.38411.378229.E0
14. Facts and Figures 2001. J Tinke A Griens, Foundation for Pharmaceutical Statistics: The Hague; The Netherlands 2001 http://www.sfk.nl
15. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. RM Herings A Bakker BH Stricker G Nap, J Epidemiol Community Health 1992 46 136 40 1349911 10.1136/jech.46.2.136
16. Medical Innovation: A Diffusion Study. JS Coleman E Katz H Menzel, The Bobbs-Merril Company, Inc.: New York 1966
17. Diffusion of Innovations. E Rogers, New York: Free Press 1995
18. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. A Jacoby M Smith M Eccles, Br J Gen Pract 2003 53 120 5 12817357
19. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. MI Jones M Greenfield CP Bradley, BMJ 2001 323 378 85 11509431 10.1136/bmj.323.7309.378
20. What happens to long-term medication when general practice patients are referred to hospital? W Himmel M Tabache MM Kochen, Eur J Clin Pharmacol 1996 50 253 7 10.1007/s002280050103 8803514
21. The influence of specialists on prescribing by GPs. A qualitative study. J Robertson CJ Treloar A Sprogis DA Henry, Aust Fam Physician 2003 32 573 6 12901220
22. AstraZeneca digs in over advertising criticisms. B Burton, BMJ 2004 328 1035a 10.1136/bmj.328.7447.1035-a
23. Should rosuvastatin be withdrawn from the market? SR Florentinus ER Heerdink OH Klungel A de Boer, Lancet 2004 364 1577 author reply 1578-9. 10.1016/S0140-6736(04)17301-7 15519621
24. FDA warns Merck over its promotion of rofecoxib. D Josefson, BMJ 2001 323 767a 10.1136/bmj.323.7316.767
25. Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. SR Florentinus MW Nielsen L van Dijk HG Leufkens EH Hansen ER Heerdink, Eur J Clin Pharmacol 2005 62 157 159 10.1007/s00228-005- 0891-z
26. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. SR Florentinus ER Heerdink A de Boer L van Dijk HG Leufkens, Pharmacoepidemiol Drug Saf 2005 14 437 441 10.1002/pds.1123 15937867
27. Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. HG Leufkens J Urquhart BH Stricker A Bakker H Petri, J Epidemiol Community Health 1992 46 428 32 1431721 10.1136/jech.46.4.428